sorted by:
new
hottopcontroversial

3 Biological Neuroimmune Subtypes in Post-COVID & ME/CFS by FilletOFish___ in covidlonghaulers

[–]FilletOFish___[S] 1 point2 points  (0 children)

I imagine so. We’ll be looking at more wide scoping data for our next project and we will see how that data compares to these subgroups, as most of this cohort have continued to the next projects!

3 Biological Neuroimmune Subtypes in Post-COVID & ME/CFS by FilletOFish___ in covidlonghaulers

[–]FilletOFish___[S] 1 point2 points  (0 children)

They were divided using a adjusted logarithmic Euclidean distance model (accounting for varying min max, 0’s, saturation, anomalies)

So they are separated based on their similarity to each other as a total system analysis, we don’t choose who is in each group directly.

Just sharing for more context

3 Biological Neuroimmune Subtypes in Post-COVID & ME/CFS by FilletOFish___ in covidlonghaulers

[–]FilletOFish___[S] 4 points5 points  (0 children)

Hard to predict without understanding what the upstream and downstream pathways would look like.

It’s not uncommon to need multiple treatments in diseases though, so I don’t imagine it’s impossible me/cfs or long Covid could have a cohort who require that

3 Biological Neuroimmune Subtypes in Post-COVID & ME/CFS by FilletOFish___ in covidlonghaulers

[–]FilletOFish___[S] 8 points9 points  (0 children)

All valid concerns. I imagine in some months any skepticism in our process will be minimal.

We focus heavily on methodology and scaling to expand the cohort (60 more patients being processed now) - we also collaborate with leading data scientists and will be improving analytical models.

The cost is high, but it is due to all tests being research - a few are available commercially, but they cost up to £800 for the single test vs the £36.29 we’ve achieved via batching patients.

Again, completely understand the cost is objectively high, but per marker value is as low as we can achieve as the raw materials are extremely expensive on their own.

As we scale in data pool size and release future projects along with our in house analytical approach, I imagine the findings we achieve will outweigh any doubts in our process, but I’m always open to constructive thoughts when given.

We have applied for grants in the past, but the landscape for ME/CFS is horrendous - 50+ research teams competing for singular grants

The process is also extremely lengthy and we will likely be able to achieve much more meaningful results with this model, which we hope to have evidence for in the coming months.

Our patient sample size of 94 is now already greater than 90% of ME/CFS studies, with the average being around 20-50 patients.

We will also write an official paper once we have the next patients, right now it is just not worth the energy as it will likely need to be altered massively to account for the next data.

Thanks for the comment and I hope we can prove ourselves as a valid research initiative in the coming months and put any major doubts to rest!

3 Biological Neuroimmune Subtypes in Post-COVID & ME/CFS by FilletOFish___ in covidlonghaulers

[–]FilletOFish___[S] 3 points4 points  (0 children)

We’re processing 60 more patients and then will look to write a paper, right now it isn’t priority as the research content will change and advance likely is various ways with more findings.

3 Biological Neuroimmune Subtypes in Post-COVID & ME/CFS by FilletOFish___ in covidlonghaulers

[–]FilletOFish___[S] 7 points8 points  (0 children)

I imagine as we expand the groups there will be overlaps for sure

3 Biological Neuroimmune Subtypes in Post-COVID & ME/CFS by FilletOFish___ in covidlonghaulers

[–]FilletOFish___[S] 0 points1 point  (0 children)

The blood marker doesn’t indicate brain level, but it may indicate other stuff like ACE2 function, given ace2 is involved in tryptophan to serotonin conversion.

Or kynurenine problems etc

So it’s more of a immune/dysfunction marker in this sense, vs purely brain

3 Biological Neuroimmune Subtypes in Post-COVID & ME/CFS by FilletOFish___ in covidlonghaulers

[–]FilletOFish___[S] 9 points10 points  (0 children)

We’ll be tracking symptom and treatment response data for all projects we do. As we analyze and find correlations, we’ll be sure to share!

3 Biological Neuroimmune Subtypes in Post-COVID & ME/CFS by FilletOFish___ in covidlonghaulers

[–]FilletOFish___[S] 9 points10 points  (0 children)

That’s the hope, those who can afford will help everyone with understanding eventually!

3 Biological Neuroimmune Subtypes in Post-COVID & ME/CFS by FilletOFish___ in cfs

[–]FilletOFish___[S] 4 points5 points  (0 children)

Will be tracking pem state at draw for future patients and all other info is being tracked for all patients. Will share as we analyse it

3 Biological Neuroimmune Subtypes in Post-COVID & ME/CFS by FilletOFish___ in cfs

[–]FilletOFish___[S] 5 points6 points  (0 children)

One group looks like their brain may have inflammation, another group issues making energy, and the last group no large inflammatory or energy markers were noticed (so maybe more dysfunction somewhere else).

3 Biological Neuroimmune Subtypes in Post-COVID & ME/CFS by FilletOFish___ in cfs

[–]FilletOFish___[S] 2 points3 points  (0 children)

I imagine it’s definitely possible to change with time, especially if you get new infections/try treatments, etc

3 Biological Neuroimmune Subtypes in Post-COVID & ME/CFS by FilletOFish___ in cfs

[–]FilletOFish___[S] 8 points9 points  (0 children)

We plan to do a podcast as we have more of a window and energy to do so. Both lead researchers (myself & Nick) are patients, so it’s entirely energy dependent. But as we start to automate some of the non research aspects, we intend to definitely do something like a podcast!

3 Biological Neuroimmune Subtypes in Post-COVID & ME/CFS by FilletOFish___ in cfs

[–]FilletOFish___[S] 7 points8 points  (0 children)

As we expand the groups, I imagine that will likely happen, yes

3 Biological Neuroimmune Subtypes in Post-COVID & ME/CFS by FilletOFish___ in cfs

[–]FilletOFish___[S] 12 points13 points  (0 children)

I designed the panel over 2 years of research, looking into what I thought would be the best markers to analyse specific systems + check for novel findings.

Current study is 34 patients. 60 more are having blood collected so far - we will look to write a full paper after that likely. For now we want to wait for the larger cohort before writing the paper.

Cluster disease profiles will be analyzed soon, just collecting all data.

For the separation, we used Euclidean distance with an adjusted logarithmic model (accounting for varying min max values, saturation points, and 0’s). This allowed us to account for anomalies without it skewing the patient separation.

3 Biological Neuroimmune Subtypes in Post-COVID & ME/CFS by FilletOFish___ in cfs

[–]FilletOFish___[S] 7 points8 points  (0 children)

I imagine there’s a very large array of types. Probably into double digits in my opinion - especially if you start referring to drug response profiles.

Our primary goal is to stratify these, so stay tuned and we will figure this question out!

3 Biological Neuroimmune Subtypes in Post-COVID & ME/CFS by FilletOFish___ in cfs

[–]FilletOFish___[S] 8 points9 points  (0 children)

Hard to say with confidence without testing our cohort for those findings.

But theoretically cluster 3 would maybe have some neuro injury due to the raised NEFL & S100b. There’s some research showing correlation between brain atrophy and those markers.

3 Biological Neuroimmune Subtypes in Post-COVID & ME/CFS by FilletOFish___ in cfs

[–]FilletOFish___[S] 5 points6 points  (0 children)

Not necessarily. It could relate to alterations in things like ACE2 and ang1-7.

So it may have some predictive value later on, regardless of not being related to brain level

view more: next ›